Micafungin Pharmazac, 50 Mg (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and fungal cell death while sparing human cells that lack this target.

The prescribed dose of Micafungin is determined by the treating clinician based on the specific infection, its severity, the patient’s renal and hepatic function, and any relevant clinical guidelines. Dosage adjustments may be required for special populations, but the exact regimen is set by the healthcare professional.

Safety data for Micafungin in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the prescribing physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis in the cell membrane. Echinocandins like Micafungin are generally effective against azole‑resistant Candida strains and have a different safety profile, making them a valuable alternative or adjunct in resistant or severe infections.

Micafungin Pharmazac should be stored at 2‑8 °C (refrigerated). The product must be kept in its original container, protected from light, and should never be frozen or shaken. Maintaining the cold‑chain ensures stability and potency of the injectable solution.

Micafungin is given as an intravenous infusion. The solution is diluted according to the manufacturer’s instructions and administered over a period typically ranging from 30 to 60 minutes, depending on the clinical protocol and patient tolerance. Administration is performed by qualified healthcare personnel in a controlled setting.

The most serious adverse reactions include severe hepatic dysfunction (marked elevation of liver enzymes or hepatitis), anaphylactic or severe allergic reactions, and rare but life‑threatening skin conditions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt recognition and medical intervention are essential if these events occur.

Micafungin should be avoided in patients with a known hypersensitivity to micafungin or any other echinocandin. Caution is also advised for individuals with pre‑existing severe liver disease, and the drug should be used only when the benefits outweigh the risks in pregnant or breastfeeding women.